Relación entre el polimorfismo rs1414334 C/G del gen HTR2C y tabaquismo en pacientes tratados con antipsicóticos atípicos

José María Rico-Gomis, Antonio Palazón-Bru, Irene Triano-García, Luis Fabián Mahecha-García, Ana García-Monsalve, Andrés Navarro-Ruiz, Berta Villagordo-Peñalver, Alicia Martínez-Hortelano, Vicente Francisco Gil-Guillén

Resumen


En pacientes psiquiátricos, otros autores han encontrado una asociación entre el alelo C del polimorfismo rs1414334 del gen HTR2C y el síndrome metabólico. Ninguno de ellos ha valorado si este alelo se asocia con el consumo de tabaco, por lo que se decidió realizar un estudio en una región española valorando esta cuestión. Estudio observacional transversal de una muestra de 166 pacientes adultos tratados con antipsicóticos atípicos en 2012-2013. Variable principal: presencia del alelo C del polimorfismo rs1414334 del gen HTR2C. Variables secundarias: número de años-paquete (número de cigarrillos al día x número de años fumando ÷ 20), edad, sexo, esquizofrenia, años diagnosticados del trastorno, criterios de síndrome metabólico y SCORE. Se construyó un modelo de regresión logística binaria por pasos para determinar asociaciones entre la variable principal y las variables secundarias del estudio y se calculó su área bajo la curva ROC (ABC). Del total de la muestra, 33 pacientes presentaron el alelo C del polimorfismo analizado (19,9%). El consumo de tabaco medio fue de 11.6 paquetes-año. El modelo multivariante arrojó los siguientes factores asociados al polimorfismo: mayor consumo tabáquico, ser mujer y no tener obesidad abdominal. El ABC fue de 0,706. Se ha encontrado asociación entre un mayor consumo de tabaco a lo largo de los años y la presencia del alelo C del polimorfismo rs1414334 del gen HTR2C. Se necesitan trabajos que corroboren nuestros resultados.

Palabras clave


Tabaquismo; Farmacogenética; Alelos; Psiquiatría

Texto completo:

PDF PDF (English)

Referencias


American Diabetes Association. (2012). Standards of medical care in diabetes–2012. Diabetes Care, 35, S11-63. doi:10.2337/dc12-s011.

American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington: American Psychiatric Press.

Azrak, C., Palazón-Bru, A., Baeza-Díaz, M. V., Folgado-De la Rosa, D. M., Hernández-Martínez, C., Martínez-Toldos, J. J. y Gil-Guillén, V. F. (2015). A predictive screening tool to detect diabetic retinopathy or macular edema in primary health care: construction, validation and implementation on a mobile application. PeerJ, 3, e1404. doi:10.7717/peerj.1404.

Barrot, C., Sánchez, C., Abellana, R., Ortega, M. y Gené, M. (2013). Polimorfismos genéticos como indicadores de la vulnerabilidad individual a la adicción al tabaco. Medicina Clínica (Barcelona), 140, 49-52. doi:10.1016/j. medcli.2012.05.041.

Conroy, R. M., Pyörälä, K., Fitzgerald, A. P., Sans, S., Menotti, A., De Backer, G., Graham, I. M.; SCORE project group. (2003). Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal, 24, 987-1003. doi:10.1016/ S0195-668X(03)00114-3.

Fletcher, P. J., Lê, A. D. y Higgins, G. A. (2008). Serotonin receptors as potential targets for modulation of nicotine use and dependence. Progress in Brain Research, 172, 361-383. doi:10.1016/S0079-6123(08)00918-7.

Gregoor, J. G., Mulder, H., Cohen, D., van Megen, H. J., Egberts, T. C., Heerdink, E. R. y van der Weide, J. (2010). Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. Journal of Clinical Psychopharmacology, 30, 702-705. doi:10.1097/JCP.0b013e3181fa05a2.

Grundy, S. M., Brewer, H. B. Jr, Cleeman, J. I., Smith, S. C. Jr y Lenfant, C; American Heart Association; National Heart, Lung, and Blood Institute. (2004). Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109, 433-438. doi:10.1161/01. CIR.0000111245.75752.C6.

Guy, E. G. y Fletcher, P. J. (2014). Responding for a conditioned reinforcer, and its enhancement by nicotine, is blocked by dopamine receptor antagonists and a 5-HT(2C) receptor agonist but not by a 5-HT(2A) receptor antagonist. Pharmacology Biochemistry and Behavior, 125, 40-47. doi:10.1016/j.pbb.2014.08.006.

Gutiérrez-Gómez, T., Cortés, E., Palazón-Bru, A., Peñarrieta- de Córdova, I., Gil-Guillén, V. F. y Ferrer-Diego, R. M. (2015). Six simple questions to detect malnutrition or malnutrition risk in elderly women. PeerJ, 3, e1316. doi:10.7717/peerj.1316.

Hanley, J. A. y McNeil, B. J. (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143, 29-36. doi:10.1148/radiology. 143.1.7063747.

Hoekstra, P. J., Troost, P. W., Lahuis, B. E., Mulder, H., Mulder, E. J., Franke, B., Buitelaar, J. K., Anderson, G. M., Scahill, L. y Minderaa, R. B. (2010). Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. Journal of Child and Adolescent Psychopharmacology, 20, 473-477. doi:10.1089/cap.2009.0071.

Houston, J. P., Kohler, J., Bishop, J. R., Ellingrod, V. L., Ostbye, K. M., Zhao, F., Conley, R. R., Poole Hoffmann, V. y Fijal, B. A. (2012). Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. Journal of Clinical Psychiatry, 73, 1077-1086. doi:10.4088/JCP.11m06916.

Klemettilä, J. P., Kampman, O., Seppälä, N., Viikki, M., Hämäläinen, M., Moilanen, E., Mononen, N., Lehtimäki, T. y Leinonen, E. (2015). Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. European Psychiatry, 30, 296-302. doi:10.1016/j.eurpsy.2014.08.006.

López-Bru, D., Palazón-Bru, A., Folgado-de la Rosa, D. M. y Gil-Guillén, V. F. (2015). Scoring System for Mortality in Patients Diagnosed with and Treated Surgically for Differentiated Thyroid Carcinoma with a 20-Year Follow- Up. PLoS One, 10, e0128620. doi:10.1371/journal. pone.0128620.

Ma, X., Maimaitirexiati, T., Zhang, R., Gui, X., Zhang, W., Xu, G. y Hu, G. (2014). HTR2C polymorphisms, olanzapine- induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta- analysis. International Journal of Psychiatry in Clinical Practice, 18, 229-242. doi:10.3109/13651501.2014.9 57705.

Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Williams, B. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 25, 1105-1187. doi:10.1097/HJH. 0b013e3281fc975a.

McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Lieberman, J. A. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32. doi:10.1016/j.schres.2005.07.014.

Mulder, H., Franke, B., van der-Beek van der, A. A., Arends, J., Wilmink, F. W., Scheffer, H. y Egberts, A. C. (2007). The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychopharmacology, 27, 338-343. doi:10.1097/JCP.0b013e3180a76dc0.

Mulder, H., Franke, B., van der-Beek van der, A. A., Arends, J., Wilmink, F. W., Egberts, A. C. y Scheffer, H. (2007). The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics Journal, 7, 318-324. doi:10.1038/sj.tpj.6500422.

Mulder, H., Cohen, D., Scheffer, H., Gispen-de Wied, C., Arends, J., Wilmink, F. W., Egberts, A. C. (2009). HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. Journal of Clinical Psychopharmacology, 29, 16-20. doi:10.1097/JCP.0b013e3181934462.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106, 3143-3421.

National Institutes of Health. (1998). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. Obesity Research, 6, 51S-209S. doi:10.1002/j.1550-8528.1998.tb00690.x.

Newcomer, J. W. y Hennekens, C. H. (2007). Severe mental illness and risk of cardiovascular disease. JAMA, 298, 1794-1796. doi:10.1001/jama.298.15.1794.

Prescott, E., Hippe, M., Schnohr, P., Hein, H. O. y Vestbo, J. (1998). Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ, 316, 1043-1047. doi:10.1136/bmj.316.7137.1043.

Ramírez-Prado, D., Palazón-Bru, A., Folgado-de la Rosa, D. M., Carbonell-Torregrosa, M. Á., Martínez-Díaz, A. M., Martínez-St John, D. R. y Gil-Guillén, V. F. (2015). A four-year cardiovascular risk score for type 2 diabetic inpatients. PeerJ, 3, e984. doi:10.7717/peerj.984.

Rico-Gomis, J. M., Palazón-Bru, A., Triano-García, I., Mahecha- García, L. F., García-Monsalve, A., Navarro-Ruiz, A., …Gil-Guillén, V. F. (2016). Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics. PeerJ, 4, e2163. doi:10.7717/peerj.2163.

Risselada, A. J., Vehof, J., Bruggeman, R., Wilffert, B., Cohen, D., Al Hadithy, A. F., … Mulder, H. (2012). Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics Journal, 12, 62- 67. doi:10.1038/tpj.2010.66.

Saccone, S. F., Hinrichs, A. L., Saccone, N. L., Chase, G. A., Konvicka, K., Madden, P. A., … Bierut, L. J. (2007). Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Human Molecular Genetics, 16, 36-49. doi:10.1093/hmg/ddl438.

Saha, S., Chant, D. y McGrath, J. (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry, 64, 1123-1131. doi:10.1001/archpsyc.64.10.1123.

San, L., Arranz, B., Arrojo, M., Becoña, E., Bernardo, M., Caballero, L., …Zorrilla, I. (2016). Clinical guideline for the treatment of dual pathology in the adult population. Adicciones, 28, 3-5. doi:10.20882/adicciones.784.

The Weizmann Institute of Science Crown Human Genome Centre. (2014). GeneCards. Retrieved at http:// www.genecards.org/cgi bin/carddisp.pl?gene=HTR2C.

Verde, Z., Santiago, C., Rodríguez González-Moro, J. M., de Lucas Ramos, P., López Martín, S., Bandrés, F., … Gómez-Gallego, F. (2011). ‘Smoking genes’: a genetic association study. PLoS One, 6, e26668. doi:10.1371/ journal.pone.0026668.

Walton, R., Johnstone, E., Munafò, M., Neville, M. y Griffiths, S. (2001). Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends in Molecular Medicine, 7, 70-76. doi:10.1016/S1471-4914(01)01915-3.

Wilson, P. W., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H. y Kannel, W. B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837-1847. doi:10.1161/01.CIR.97.18.1837.




DOI: https://doi.org/10.20882/adicciones.876

Enlaces refback

  • No hay ningún enlace refback.